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Abstract. Background: Effective treatments for
glioblastoma multiforme (GBM) are lacking due, in part, to
cellular heterogeneity. Consequently, single-target
therapeutic strategies are unlikely to succeed. Simultaneous
targeting of different neoplastic cell populations within the
same tumour may, therefore, prove of value. Neuron-glia 2
(NG2), a transmembrane chondroitin sulphate proteoglycan,
present on developing glial cells, and GD3A, a ganglioside
expressed on developing migratory glia, are re-expressed in
GBM. Materials and Methods: The aims of this study were
to conduct ‘proof of concept’ experiments in human GBM
cell lines to show that proliferative high NG2-expressing
cells and high GD3A -expressing migratory cells could be
effectively ablated using a Mab-Zap saporin immunotoxin
system. Results: The combinatorial ablation of both NG2
and GD3A-expressing cells resulted in significant reduction
in GBM cell viability compared to single epitope targeting
and controls (p<0.0001); non-neoplastic astrocytes were not
affected. Conclusion: Multiple targeting of GBM sub-
populations may, therefore, help inform novel therapeutic
approaches.
Glioblastoma multiforme (GBM) is the most common
primary adult brain tumour and unfortunately, even with the
current multimodality standard-of-care that includes maximal
safe surgical resection, post-operative radiotherapy in parallel
with temozolomide followed by adjuvant chemotherapy, the
median survival is only 14 months (1). GBM is characterized
by tumour heterogeneity, widespread tumour cell infiltration,
angiogenesis, necrosis and proliferation (2). Due to tumour
heterogeneity and the ability of tumour cells to adapt to
changes in the microenvironment, the likelihood of a one
targeted approach is low, especially when considering the
molecular genotypic sub-groups of GBMs (3-6). Antigens
that are associated with distinct and specific glioma cell
biological functions may prove useful to deliver therapies to
an area of tumour heterogeneity. In this report a ‘proof of
concept’ was tested in human GBM cell lines in which two
cell surface antigens known to be associated with distinct
and overlapping GBM cell populations were targeted to
deliver an immunotoxin. Neuron-glia 2 (NG2), also known
as chondroitin sulphate proteoglycan 4 (CSPG4), has been
well characterized in human adult brain tumours and its
expression is highly correlated with increased tumour cell
proliferation, grade of tumour, poor prognosis and
angiogenesis (7-10). NG2 is associated with increasing
histological grade of malignancy and proliferation rates in
adult glioma with an aggressive molecular signature (11-13).
NG2 is not detectable in normal quiescent vasculature and
expression in neovasculature is limited to neovascular
pericytes (9, 14). A study comparing proliferation,
clonogenic and tumourigenic capacities of NG2-positive
glioma cells with their negative counterparts revealed that
NG2-positive cells had a higher level of proliferation,
exhibited higher tumourigenic capabilities and over-
expressed genes associated with aggressive tumourigenicity
(13). Targeting NG2 by knockdown studies reduces tumour
growth and angiogenesis in pre-clinical models of
glioblastoma and melanoma. In the glioma model, targeting
NG2 resulted in reductions in tumour growth and oedema
levels, angiogenesis and normalised vascular function.
Furthermore, it has been established that NG2 promotes
tumour progression by multiple mechanisms and represents
an accessible target for therapy (10).  
77
Correspondance to: Dr. Samantha Higgins, Cellular & Molecular
Neuro-oncology Group, Institute of Biomedical & Biomolecular
Sciences, School of Pharmacy & Biomedical Sciences, White Swan
Road, University of Portsmouth, Portsmouth PO1 2DT, UK. Tel:
+44 02392842125, e-mail: samantha.higgins@port.ac.uk
Key Words: NG2 proteoglycan, GD3A, immunoablation, saporin,
glioma.
ANTICANCER RESEARCH 35: 77-84 (2015)
Dual Targeting NG2 and GD3A Using Mab-Zap Immunotoxin
Results in Reduced Glioma Cell Viability In Vitro
SAMANTHA C. HIGGINS1, HELEN L. FILLMORE1, KEYOUMARS ASHKAN2, 
ARTHUR M. BUTT3 and GEOFFREY J. PILKINGTON1
1Cellular and Molecular Neuro-oncology Research Group and 3Cellular Neurophysiology Research Group,
Cellular and Molecular Medicine Research Division, Institute of Biomedical and Biomolecular Sciences,
School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, U.K.;
2Department of Neurosurgery, King’s College Hospital, London, U.K.
0250-7005/2015 $2.00+.40
GD3, an oncofetal ganglioside, is crucial in cell migration
during normal brain development. Upon brain maturation, GD3
accumulates and is responsible for the death of supernumerary
progenitor cells during embryonic brain maturation (15).
However, in neoplastic gliomas, GD3 is re-expressed and
involved in cell invasion (16). In addition, modification of GD3
to GD3A by sialic acid acetylation is associated with cell
survival (17). GD3 contains two sialic acid residues,
sequentially attached to the galactose residue. The most
common post-synthetic modification of GD3 is O-acetylation
at the C9 position of its terminal sialic acid. The resulting 9-
O-acetyl GD3 (GD3A) is expressed in a developmentally
regulated and tissue-specific manner and has been
demonstrated in a variety of tumours (18, 19). O-acetylation of
GD3 by tumour cells may represent an important strategy
adopted to evade acute GD3 accumulation during cell stress
and to enhance survival. In support of this, it was recently
demonstrated that GBM cells undergo apoptosis when a gene
therapy approach targets the deacetylation of GD3A (17). 
Although there is some overlap of expression, NG2 and
GD3 are associated with two distinct tumour cell populations
(NG2, highly proliferative tumour cells and GD3/GD3A,
tumour cell survival and migration) (9). Herein, we examined
the ability of an NG2 and a GD3A antibody to deliver a
secondary antibody conjugated to the ribosome-inactivating
protein saporin (Mab-Zap; Advanced Targeting Systems, San
Diego, CA, USA) (Figure 1). Saporin is a ribosome-
inactivating protein derived from the plant Saponaria
officinalis, known to induce apoptosis and cell-cycle arrest.
On antigen-antibody binding, the immunotoxin is
internalized by the target cells and the enzymatic fragment
of the toxin translocates to the cytosol, where it induces
ribosomal damage, inhibits protein synthesis and causes cell
death (20). This system has been used for targeting tumour
antigens, including the receptor protein tyrosine phosphatase
β in a model of GBM (21), the antigen tomoregulin (22) and
prostate-specific membrane antigen (PMSA) in prostate
cancer cell lines (23), as well as the CSPG4 (also known as
NG2) antigen in a malignant mesothelioma model (24).
Although the use of immuotoxins coupled with single
tumour-specific ligands is not novel, we used this established
method to demonstrate the feasibility of selectively targeting
subpopulations of glioma. Given the functional importance
of both NG2 and GD3A in GBM, this may serve as a
promising dual target in which multiple sites within a highly
heterogeneous tumour could be pursued.
Materials and Methods
Ethics statement. Biopsies from glioma patients were obtained under
Ethics permissions LREC 00-173 or KCH 11-094 or 11/SC/0048 in
accordance with the National Research Ethics Service (NRES) and
the study was approved through ethics committees for the University
of Portsmouth and King’s College Hospital, London. All patients
consented to the use of biopsy material for research purposes.
Consent forms were read to and duly signed by participating
patients prior to surgery.
Cell culture. Human-authenticated glioma-derived cell lines (25)
established from primary cultures of biopsy-derived brain tumours
(UP-007, UP-019 and UP-032; Table I) were maintained as
monolayer cultures in Dulbecco’s modified Eagle’s medium
(DMEM – without pyruvate, with glucose, Glutamax and Phenol
Red) (Gibco, Paisley, Renfrewshire, UK) and supplemented with
10% heat inactivated foetal bovine serum (FBS) (Sigma-Aldrich,
Gillingham, Dorset, UK) and referred to as complete media. All
cells were washed with Hank’s balanced salt solution (HBSS)
(Gibco) and harvested using TrpLE™ Express (Gibco). A primary
astrocyte culture (UP-010), obtained from a patient undergoing a
temporal lobe resection for epilepsy control, was also established.
Evaluation of NG2 and GD3A expression on human cell lines. The
expression of NG2 and GD3A was quantitatively examined by
flow cytometry. Cells were harvested and incubated with 100 μl
pre-diluted primary antibody for 30 min at 40C. NG2 antibody
(R&D Systems, Abingdon, Oxfordshire, UK) was used at a 1:1000
dilution (human NG2/MCSP, mouse IgG, catalogue # MAB2585).
GD3A antibody (Novus Biologicals, Cambridge, Cambridgeshire,
UK) was used at a 1:50 dilution (non-species specific OAcGD3,
mouse IgG, catalogue # NB120-6218). Negative control samples
were incubated with a mouse IgG isotype control antibody
(catalogue # I-2000, Vector Labs, Peterborough, Cambridgeshire,
UK) at the same concentration as primary antibodies. Samples
were then incubated with 100 μl secondary Alexa Fluor 488
(Invitrogen, Paisley, Renfrewshire, UK) conjugated antibody for
15 min in the dark and at 4˚C. Samples were washed with buffer
through centrifugation and the supernatant discarded. Cell pellets
were re-suspended in PBS and 2% goat serum (GS), transferred to
FACS tubes and analysed. Analysis was performed on a four-
colour multi-parameter BD Biosciences FACS Calibur (BD
Biosciences, Oxford, Oxfordshire, UK). 
The expression of NG2 and GD3A was examined by double-
labelled image cytometry. Cells were harvested and incubated with
100 μl pre-diluted NG2 primary antibody for 30 min at 4˚C.
Negative control samples were incubated with a mouse IgG
isotype control antibody at the same concentration as primary
antibodies. This step was omitted from the negative control
samples. Samples were washed with buffer and then incubated
with 100 μl secondary Alexa Fluor 488 conjugated antibody for
15 min in the dark and at 4˚C. Samples were washed with buffer
through centrifugation and the supernatant discarded. Samples
were then incubated with the second primary antibody GD3A for
30 min at 4˚C, washed with buffer and then incubated with
secondary Alexa Fluor 568 conjugated antibody for 15 min in the
dark and at 4˚C. Samples were washed with buffer and the
supernatant discarded. Cell pellets were re-suspended in PBS and
2% FBS, before analysis with a NucleoCounter NC3000 image
cytometer (Chemometec, Allerød, Denmark). 
Immunocytochemistry. Cells were grown to confluency on cover
slips in duplicate and were fixed in 4% paraformaldehyde (PFA)
(Sigma-Aldrich) for 2 min and stained with NG2 and GD3A
antibodies described previously. Cells were incubated with primary
NG2 antibody used at dilution 1:1000. Following three washes with
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PBS, 1:500 of the secondary antibody anti-mouse Alexa Fluor 568
(Invitrogen) was added for thirty minutes in the dark followed by a
final wash with PBS. The cells were then washed three times in PBS
and re-probed with GD3A primary antibody (1:200) and secondary
anti-mouse Alexa Fluor 488 and, finally, nuclear counterstained with
Hoechst Blue (10 μg/ml) (Sigma-Aldrich) for five seconds. The
cells were washed three times in PBS, mounted and examined using
a Zeiss Axioimager epifluorescence microscope with excitation and
barrier filters for fluorescein isothiocyanate (FITC), Texas Red and
4’,6-diamidino-2-phenylindole (DAPI) (Carl Zeiss Ltd., Cambridge,
Cambridgeshire, UK). The primary antibody was omitted in the
negative controls. 
Dual targeted NG2/GD3 cell ablation in monolayer cultures using
Mab-Zap immunotoxin. Mab-Zap (Advanced Targeting Systems,
San Diego, CA, USA) is a chemical conjugate of affinity-purified
goat anti-mouse IgG and Saporin. Saporin is a ribosome-inactivating
protein with a molecular weight of 30 kDa from the seeds of the
plant Saponaria officinalis. Second immunotoxins are conjugations
of a secondary antibody to Saporin. This second immunotoxin uses
the secondary antibody (affinity purified goat anti-mouse IgG) to
“piggyback” onto the mouse IgG primary antibody. Once the Mab-
Zap is internalised, Saporin breaks away from the targeting agent
and inactivates ribosomes, which causes protein inhibition and,
ultimately, cell death.
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Table I. Human glioma and non-neoplastic astrocyte cell cultures and their histopathological grading.
Cell lines Age (years) Gender No Passage Histopathological grading
UP-007 71 Male 25 GBM (Grade IV)
UP-019 68 Female 9 GBM (Grade IV)
UP-032 71 Male 9 Anaplastic Astrocytoma (AA Grade III)
UP-010 Unknown Male 4 Temporal lobe resection-derived non-neoplastic astrocytes
GBM, Glioblastoma multiforme.
Figure 1. A schematic diagram depicting the sequential and dual secondary Mab-Zap immunotoxin approach in which a heterogeneous population
of cells are first treated with NG2 antibody-conjugated immunotoxin and then hit with a second treatment using GD3A antibody-conjugated
immunotoxin. The antibody-conjugated immunotoxin (saponin) binds to the cell surface antigen, is internalized and cell death occurs by inactivating
ribosomes specifically killing cells expressing the antigens.
Cells were harvested, counted using a ViCell XR Coulter Counter
(Beckman Coulter UK, High Wycombe, Buckinghamshire, UK) and
seeded into a 96-well plate at a density of 1×104 in a final volume
of 100 μl complete clear DMEM supplemented with glutamax and
10% FBS. Cells were returned to the incubator and allowed to
adhere overnight. Mab-Zap and primary antibodies (same as above)
were made up fresh as per the treatment schedule and allowed to
conjugate for 30 minutes at room temperature. Two 96-well plates
were set up for each cell line per treatment; both plates were
initially treated with either 1 μg/ml or 5 μg/ml NG2/Mab-Zap and
incubated for 72 hours. After this time, the first plate was taken
forward for the cell proliferation assay (see below) and the second
plate had the NG2/Mab-Zap treatment removed and was then
sequentially treated with either 1 μg/ml or 5 μg/ml GD3A /Mab-Zap
and incubated for a consecutive 72 hours, time after which these
plates were then taken forward for the MTS assay. The negative
controls included omission of immunotoxin treatment and inclusion
of either primary antibody alone or Mab-Zab alone to investigate
toxicity of both compounds unconjugated. 1M NaOH was added to
the positive control wells.
MTS assay (CellTitre 96®AQueous non-radioactive cell
proliferation assay). The CellTitre 96®AQueous non-radioactive cell
proliferation assay (Promega, Southampton, Hampshire, UK) was
utilised to determine cell viability of the human cell lines after
treatment as per the manufacturer’s guidelines. The absorbance
was then read using the Labtech POLAR Star Optima plate reader
at 490nm (BMG LABTECH Ltd., Aylesbury, Buckinghamshire,
UK) and viability calculated from the ratio between control
samples and test samples.
Statistical analysis. All data are expressed as mean values. All
concentrations are expressed as the final concentrations to which
cells were exposed. Statistical analysis was performed on the data
using a one way analysis of variance (ANOVA) followed by the
Tukey’s multiple comparison post-test with a probability of <0.05
being regarded as significant. The software package GraphPad
Prism 3.02 (GraphPad Software, San Diego, CA, USA) was used to
calculate the statistical tests. 
Results
Human glioma cell lines contain distinct NG2-positive cells and
overlapping populations with cells positive for GD3A. The
expression profile of NG2 and GD3A in GBM cell lines was
determined using flow cytometry. Three primary established
GBM cell lines (UP-007, UP-019 and UP-032) obtained from
patient biopsies were examined for NG2 and GD3A expression
and compared to an established primary astrocyte culture (UP-
010) obtained from a patient who had undergone a temporal lobe
resection for intractable epilepsy. Compared to the astrocyte cell
line, the GBM cell lines, UP-007, UP-019 and UP-032, contain
high NG2 cell surface expression with over 90% of total cell
population (97.6%, 95.9% and 96.4%, respectively) as examined
by flow cytometry (Figures 2a-c). The control non-neoplastic
human astrocytes contained approximately 5.48% NG2 positivity
of the total population (Figure 2d). 
GD3A expression was also examined in the glioma cell
lines and the astrocyte cell line. While the population of NG2-
positive cells in the glioma cell lines were over 90%, GD3A-
positive cells were lower and varied between the cell lines
(Figures 2e-g). The GBM cell lines, UP-007, UP-019 and UP-
032, contain GD3A-positive cells (47.3%, 21.2% and 43.1%,
respectively, Figures 2e-g). The control non-neoplastic human
astrocytes contained approximately 1.5% GD3A positivity of
the total population (Figure 2h). These results suggest some
overlap with NG2 and GD3A in the glioma cell lines. To
examine this more closely, the UP-007 cell line was double-
labelled with antibodies for both NG2 and GD3A and
subjected to immunocytochemistry and flow cytometric
analysis. These data confirmed an overlap with cells positive
for NG2 and GD3A, as well as distinct and separate NG2-
and GD3A-positive populations as seen in UP-007 cells
(Figure 3). There was co-expression of NG2 and GD3A in
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Figure 2. Flow cytometric analysis of NG2 and GD3A expression in glioma cells. Cells were incubated with either NG2 or GD3A antibody and Alexa
Fluor 488 (left-handed peaks) and measured using the FL1 channel. Expression was compared to an isotype control antibody (right-handed peaks).
NG2 expression was measured as a) UP-007 97.61% positive; b) UP-019 95.9% positive; c) UP-032 96.36% positive d) UP-010 5.48% positive.
GD3A expression was measured as e) UP-007 47.27% positive; f) UP-019 21.18% positive; g) UP-032 45.13% positive h) UP-010 1.52% positive.
79.7% of the cell population with two distinct populations
(NG2-positive, 10.9% and GD3A-positive, 5.7%).
Treatment of human glioma cells with NG2 and GD3A
immunotoxin. Glioma cell viability was reduced when cells
were treated with NG2 immunotoxin alone when compared to
non-neoplastic astrocytes (Figure 4a, p<0.0004). When glioma
cell lines were sequentially treated with NG2 immunotoxin
followed by GD3A immunotoxin there was also a significant
decrease in cell viability (p<0.0001), while no effect was seen
in the non-neoplastic astrocyte cell line (Figure 4b). In both
experimental paradigms, the effect of reducing viability was
further enhanced with increasing the immunotoxin to 5 μg/ml
from 1 μg/ml (Figure 4a and b, p<0.0004). UP-007 cell
viability was reduced from approximately 30% (1 μg/ml
NG2/GD3A:Mab-Zap) to 5.0% (5 μg/ml NG2/GD3A:Mab-
Zap) (p<0.0004), for UP-019 28.88% to 6.81% (p<0.0004)
and for UP-032 29.24% to 6.13% (p<0.0004) (Figure 4b).
Glioma cell viability was not affected by treatment with
primary antibody alone or with Mab-Zap immunotoxin alone
(Table II) supporting the fact that both the antibody and the
immunotoxin are needed for this effect on cell viability. 
Discussion
As previously described in the literature, NG2 expression on
glioma cells is indicative of increased histological
malignancy (11); moreover, NG2-positive cells demonstrate
higher levels of proliferation, higher tumourigenic
capabilities and a more aggressive phenotype (13). High
NG2 expression correlates with decreased survival outcomes
by mediating resistance to chemotherapy (26) and
radiotherapy (14). NG2 represents an attractive target for the
secondary immunotoxin (ITX) approach to cancers. 
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Figure 3. Co-expression analysis in UP-007 cell line. a) Representative image of double labelling with NG2 and GD3A. Red, NG2 and Green GD3A.
b) Cytometric dot plot of NG2 (green) and GD3A (red) double labelling of UP-007. Less than four percent (3.8%) of cells in the bottom left quadrant
are negative for both NG2 and GD3A, 10.9% of cells in the bottom right quadrant are positive for NG2 only, 5.7% of cells in the top left quadrant
are positive for GD3A only and 79.7% of cells in the top right quadrant are positive for both NG2 and GD3A. 
Table II. Percentage cell viability after cell treatment with primary antibody alone and Mab-Zap alone as determined by the MTS assay. 
Cell line No treatment Primary antibody alone (1:1000) Mab-Zap alone (1 μg/ml) Mab-Zap alone (5 μg/ml)
UP-007 100% 99.43% 98.89% 97.66%
UP-019 100% 97.90% 97.10% 97.97%
UP-032 100% 98.21% 97.25% 98.26%
UP-010 100% 97.67% 98.56% 98.11%
No significance was found between treatment groups p>0.005.
Antibody-based immunotherapy against NG2 expression
in melanoma has been extensively investigated. Monoclonal
antibodies (mAbs) have been used as the vehicle to
selectively deliver radionucleotides and toxins to the tumour
cells (27, 28). NG2 is expressed by the tumour vasculature,
as well as in the tumour, therefore this form of targeted-
therapy may offer several advantages over tumour-restricted
therapies. Other than tumour-associated vascular pericytes
and oligodendrocyte precursor cells (OPCs) in the brain,
NG2 has restricted distribution in normal tissues (29). 
The expression of NG2 is associated with proliferative
activity in glioma, whereas pro-survival/anti-apoptosis, as well
as invasion, is associated with the expression of GD3A. Spatial
distribution of NG2 and GD3 in tumour biopsies has been
reported indicating that NG2 expression is confined to the
main tumour mass and is reduced towards the tumour
periphery, while GD3 expression is evident both in the main
tumour mass and at the brain/tumour interface (7). Our results,
utilising human glioma and astroctye cell lines, demonstrate
the feasibility of targeting NG2-positive gliomas without
affecting the viability of NG2-negative astrocytes. This
involvement of NG2 in multiple aspects of tumour biology
makes this proteoglycan an attractive candidate for future
therapies against cancer. NG2 may provide a suitable target
for cytotoxic therapy, particularly in harness with approaches
aiming to target the shared glioma cell antigen GD3A. Herein,
we have conducted ‘proof of principle’ experiments and
demonstrated the possibility of targeting two overlapping and
distinct populations of cells with a secondary immunotoxin
approach. This system demonstrated the ability to target
different antigens with the sequential treatment of ablating
NG2-positive cells and then GD3A-positive cells, respectively.
These results suggest the feasibility of selectively targeting
subpopulations of glioma cells and may lead to improved
therapeutics in which multiple sites, within a highly
heterogeneous tumour, could be targeted.
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